Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + dalpiciclib + exemestane neoadjuvant therapy for HR-positive HER2-low breast cancer
ChiCTR2400093491Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Dec 2024
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin, dalpiciclib and exemestane in breast cancer, sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Breast pathological complete response. Started Dec 2024; status: recruiting.
02
Drugs
disitamab vedotindalpiciclibexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400093491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093491.